Superiority
A steadfast commitment to Vitamin K2 research and development assures MenaQ7® is a superior product based on the following important criteria:
- High Purity
An essential characteristic of a superior Vitamin K2 ingredient is the level of purity, which is important for the overall quality and efficacy of the end product.
Products with a high level of unknowns or impurities offer less of the beneficial effects of the MK-7 molecule. That is not the case with MenaQ7®.
Every batch of MenaQ7® produced is controlled by HPLC.
MenaQ7® purity is defined by:
— High concentration of up to 97% of pure Vitamin K2
— 99,8% of all-trans menaquinone-7 (MK-7)
- All-trans MK-7:
Isomeric purity defines the quality of and speaks to the bioactivity of Vitamin K2 as MK-7. Natural vitamin K in the all-trans configuration , which has been proven to be the biologically active form – meaning that this configuration will activate the carboxylase enzyme, enabling it to further activate proteins like coagulation factors, Osteocalcin, and MGP, among others.
Research has established the efficacity of the trans-form, while the cis–isomers benefit and activity in the body is unknown.
MenaQ7® is an all-trans form of Vitamin K2 as MK-7. Our multistep patented processes successfully deliver nature-identical menaquinone-7.
The diverse MenaQ7® product lines utilize the highest quality, bioactive Vitamin K2 as MK-7 derived by the natural process of fermentation.
- Safety
MenaQ7® materials are given Novel Food status by the European Food Safety Authority (EFSA). The scientific safety evaluation performed by EFSA is a solid confirmation to the public that the product is safe and beneficial.
MenaQ7® is also self-affirmed GRAS (generally recognized as safe) in the United States, a designation by the U.S. Food and Drug Administration (FDA) stating that all necessary research, including the formation of an expert panel to review safety concerns, has been performed.
Recommended daily intake of vitamin K is 120 mcg/day (US) for men, 90 mcg/day (US) for women, and 30-55 mcg/day (US) for children.
A dose and safety study done by Theuwissen et al (2012), showed that extra intake of MK-7, as MenaQ7®, at nutritional doses around RDI improved the activation of proteins like Osteocalcin and Matrix Gla. No adverse effects of thrombin was observed.
NOTE: Vitamin K is needed for proper activation of several coagulation (blood-clotting) proteins, which is why it is recommended that patients receiving oral-anticoagulant (OAC) treatment do not take MK-7 supplements without consulting with their medical doctor.